COVAXIN phase 3 trial data to be made public in July 2021

COVAXIN phase 3 trial data: As per the interim analysis of the Covaxin trials, the vaccine's overall efficacy is 78 percent against symptomatic disease and 100 percent against hospitalizations.  CURRENT AFFAIRS